Last reviewed · How we verify

NCT06625047

Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy

Completed Phase 4 Last updated 31 December 2025
What this trial tests

Phase 4 trial testing Assessment in Astrocytoma, IDH-Mutant in 30 participants. Completed in 12 November 2025.

Timeline
7 October 2024
Primary endpoint
12 November 2025
12 November 2025

Quick facts

Lead sponsorMayo Clinic
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposehealth services research
Enrollment30
Start date7 October 2024
Primary completion12 November 2025
Estimated completion12 November 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Astrocytoma, IDH-Mutant or Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase IV trial compares patient satisfaction with telehealth versus in-person neuro-oncology assessments among glioma patients receiving oral chemotherapy. Gliomas are the most common primary central nervous system cancer and are associated with a high symptom burden, such as drowsiness, fatigue, memory difficulty, and difficulty communicating. Care at a high volume center is associated with an overall survival benefit, however, many patients may have physical or financial difficulties preventing access to these centers. Telehealth visits use computers, cameras, videoconferencing, the internet, satellite, and wireless communications to deliver healthcare, while in-person visits require the interaction to take place in the physical presence of someone else. Telehealth neuro-oncology assessments may be preferable compared to in-person assessments in glioma patients receiving oral chemotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Protocol for neuro-oncology anywhere 242: Pilot study evaluating telehealth and in-person assessments in patients with glioma receiving oral chemotherapy.
    Sener U, Galloway T, Neth B, Uhm J, et al · · 2026 · PMID 41567708 · DOI 10.1016/j.conctc.2025.101593

Verify or expand the search:

Other trials of Assessment

Trials testing the same drug.

Other recruiting trials for Astrocytoma, IDH-Mutant

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06625047.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing